IL155194A0 - Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same - Google Patents

Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Info

Publication number
IL155194A0
IL155194A0 IL15519401A IL15519401A IL155194A0 IL 155194 A0 IL155194 A0 IL 155194A0 IL 15519401 A IL15519401 A IL 15519401A IL 15519401 A IL15519401 A IL 15519401A IL 155194 A0 IL155194 A0 IL 155194A0
Authority
IL
Israel
Prior art keywords
pravastatin
epi
substantially free
compositions containing
lactone
Prior art date
Application number
IL15519401A
Original Assignee
Biogal Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22897222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL155194(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogal Pharmaceutical Co Ltd filed Critical Biogal Pharmaceutical Co Ltd
Publication of IL155194A0 publication Critical patent/IL155194A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/34—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D309/36—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C07D309/38—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms one oxygen atom in position 2 or 4, e.g. pyrones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/04—Sodium compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C67/00—Preparation of carboxylic acid esters
    • C07C67/48—Separation; Purification; Stabilisation; Use of additives
    • C07C67/52—Separation; Purification; Stabilisation; Use of additives by change in the physical state, e.g. crystallisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrane Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL15519401A 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same IL155194A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23827800P 2000-10-05 2000-10-05
PCT/US2001/031230 WO2002030415A1 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Publications (1)

Publication Number Publication Date
IL155194A0 true IL155194A0 (en) 2003-11-23

Family

ID=22897222

Family Applications (1)

Application Number Title Priority Date Filing Date
IL15519401A IL155194A0 (en) 2000-10-05 2001-10-05 Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Country Status (18)

Country Link
EP (1) EP1330245A4 (en)
JP (6) JP3737801B2 (en)
KR (1) KR20030059173A (en)
CN (1) CN1468098A (en)
AU (1) AU2002211462A1 (en)
CA (1) CA2422744A1 (en)
CZ (1) CZ20031166A3 (en)
HR (1) HRP20030347A2 (en)
HU (1) HUP0400913A2 (en)
IL (1) IL155194A0 (en)
IS (1) IS6766A (en)
MX (1) MXPA03002963A (en)
NO (1) NO20031532L (en)
NZ (1) NZ525631A (en)
PL (1) PL361230A1 (en)
SK (1) SK5232003A3 (en)
WO (1) WO2002030415A1 (en)
ZA (1) ZA200302313B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2002114072A (en) * 1999-11-30 2004-07-20 Биогал Джиоджисзерджиар РТ (HU) METHOD FOR ISOLATING STATIN COMPOUNDS FROM FERMENTATION BOIL
EP1481674B1 (en) * 1999-11-30 2008-01-02 TEVA Gyógyszergyár Zártkörüen Müködö Részvénytársaság Process for recovering statin compounds from a fermentation broth
EP1798214A3 (en) * 1999-11-30 2007-08-01 Teva Gyogyszergyár Zártköruen Muködo Részvenytarsaság Process for recovering statin compounds from a fermentation broth
CA2394200C (en) 1999-12-14 2006-10-03 Biogal Gyogyszergyar Rt. Novel forms of pravastatin sodium
IL155194A0 (en) * 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
JP3236282B1 (en) * 2000-10-16 2001-12-10 三共株式会社 How to purify pravastatin
GB0218781D0 (en) 2002-08-13 2002-09-18 Astrazeneca Ab Chemical process
EP1452519A1 (en) * 2003-02-25 2004-09-01 Balkanpharma-Razgrad AD Method for the isolation and purification of pravastatin sodium
GB0312896D0 (en) 2003-06-05 2003-07-09 Astrazeneca Ab Chemical process
UY28501A1 (en) 2003-09-10 2005-04-29 Astrazeneca Uk Ltd CHEMICAL COMPOUNDS
GB0324791D0 (en) 2003-10-24 2003-11-26 Astrazeneca Ab Chemical process
DE202004020671U1 (en) * 2003-11-24 2005-12-08 Teva Gyogyszergyar Reszvenytarsasag pravastatin
US7642287B2 (en) 2004-08-06 2010-01-05 Transform Pharmaceuticals, Inc. Statin pharmaceutical compositions and related methods of treatment
ES2254028B1 (en) * 2004-11-29 2007-03-01 Ercros Industrial, S.A. PROCEDURE FOR OBTAINING PRAVASTATIN SODIUM PURIFIED.
MX2007010431A (en) * 2005-02-25 2007-10-11 Teva Pharma Process of purifying tadalafil.
JP4813841B2 (en) * 2005-07-25 2011-11-09 キユーピー株式会社 Method for producing pravastatin sodium
HU229260B1 (en) * 2010-11-29 2013-10-28 Egis Gyogyszergyar Nyrt Process for preparation of rosuvastatin salts
CN114031496B (en) * 2021-11-30 2024-09-27 广东蓝宝制药有限公司 A method for preparing high-purity pravastatin 1,1,3,3-tetramethylbutylamine

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3378441A (en) * 1963-10-17 1968-04-16 S B Penick & Company Tetraene antibiotic purification
JPS5221594B2 (en) * 1973-09-29 1977-06-11
NL7601227A (en) * 1975-02-07 1976-08-10 Glaxo Lab Ltd PROCESS FOR PREPARING A NEW ANTIBIOTIC.
US4231938A (en) * 1979-06-15 1980-11-04 Merck & Co., Inc. Hypocholesteremic fermentation products and process of preparation
DK149080C (en) * 1980-06-06 1986-07-28 Sankyo Co METHOD FOR PREPARING ML-236B CARBOXYLIC ACID DERIVATIVES
JPS572240A (en) * 1980-06-06 1982-01-07 Sankyo Co Ltd Ml-236b derivative
JPS5889191A (en) * 1981-11-20 1983-05-27 Sankyo Co Ltd Preparation of 3-hydroxy-ml-236b derivative
JPS5890509A (en) * 1981-11-25 1983-05-30 Sankyo Co Ltd Composition for remedy of hypercholesterolemia
JPH01190661A (en) * 1988-01-22 1989-07-31 Konishi Kagaku Kogyo Kk Purification of 4,4'-dihydroxydiphenylsulfone
JP2739328B2 (en) * 1988-09-14 1998-04-15 日本ケミファ株式会社 Purification method of benzimidazole compound
US5202029A (en) * 1991-03-13 1993-04-13 Caron Kabushiki Kaisha Process for purification of hmg-coa reductase inhibitors
NZ250609A (en) * 1992-12-28 1995-07-26 Sankyo Co Hexahydronaphthalene esters and ring closed lactones; preparation and medicaments
JPH06256278A (en) * 1993-03-03 1994-09-13 Nissan Chem Ind Ltd Optically active alpha-carbamoylalkanoic acid derivative and its production
CA2126365C (en) * 1993-07-06 1999-08-24 Steven W. Felman Recovery of citric acid from impure process streams by addition of strong acids and salts thereof
ES2112042T3 (en) * 1994-03-31 1998-03-16 Cultor Oy PROCEDURE FOR THE RECOVERY OF NATAMYCIN.
SI0784605T1 (en) * 1995-08-03 2000-08-31 Dsm N.V. Selective process for the deacylation of acylated compounds
JPH09124655A (en) * 1995-11-01 1997-05-13 Sankyo Co Ltd Novel squalene synthase inhibitory compounds
EP0877089A1 (en) * 1997-05-07 1998-11-11 Gist-Brocades B.V. HMG-CoA reductase inhibitor preparation process
SI20072A (en) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. PROCEDURE OF PREPARATION OF INHIBITORS OF HMG-CoA REDUCTASE
SI20070A (en) * 1998-09-18 2000-04-30 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. NOVEL SALTS OF INHIBITORS OF HMG-CoA REDUCTASE
JP2000229855A (en) * 1998-12-07 2000-08-22 Satoshi Takebe Pravastatin sodium tablet
IL144697A0 (en) * 1999-02-03 2002-06-30 Teva Pharma Microbial process for preparing paravastatin
HUP9902352A1 (en) * 1999-07-12 2000-09-28 Gyógyszerkutató Intézet Kft. Process for producing pravastatin by microbiological way
RU2002114072A (en) * 1999-11-30 2004-07-20 Биогал Джиоджисзерджиар РТ (HU) METHOD FOR ISOLATING STATIN COMPOUNDS FROM FERMENTATION BOIL
IL155194A0 (en) * 2000-10-05 2003-11-23 Biogal Pharmaceutical Co Ltd Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same

Also Published As

Publication number Publication date
IS6766A (en) 2003-04-01
SK5232003A3 (en) 2004-06-08
HUP0400913A2 (en) 2006-11-28
AU2002211462A1 (en) 2002-04-22
JP2013128486A (en) 2013-07-04
JP2006036781A (en) 2006-02-09
CZ20031166A3 (en) 2004-04-14
NZ525631A (en) 2005-05-27
ZA200302313B (en) 2004-03-25
WO2002030415A9 (en) 2002-10-31
NO20031532D0 (en) 2003-04-04
EP1330245A1 (en) 2003-07-30
JP2015212300A (en) 2015-11-26
CN1468098A (en) 2004-01-14
JP2004510817A (en) 2004-04-08
JP3737801B2 (en) 2006-01-25
HRP20030347A2 (en) 2005-04-30
PL361230A1 (en) 2004-10-04
JP2009268479A (en) 2009-11-19
JP2005013238A (en) 2005-01-20
WO2002030415A1 (en) 2002-04-18
MXPA03002963A (en) 2005-01-25
CA2422744A1 (en) 2002-04-18
NO20031532L (en) 2003-04-04
EP1330245A4 (en) 2004-10-20
KR20030059173A (en) 2003-07-07

Similar Documents

Publication Publication Date Title
IL155194A0 (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU3459702A (en) Branched primary alcohol compositions and derivatives thereof
HUP0302297A3 (en) Substituted thioacetamides and pharmaceutical compositions containing them
AU2001281140A1 (en) Anti-plasmodium compositions and methods of use
IL137363A0 (en) Pharmaceutical compositions containing mupirocin
HUP0303184A3 (en) Substituted c-cyclohexylmethylamine derivatives and pharmaceutical compositions containing them
GB2368014B (en) Pharmaceutical composition containing citalopram
NZ524418A (en) Highly purified simvastatin compositions
HUP0303204A3 (en) 1-methylcarbapenem derivatives and pharmaceutical compositions containing them
IL150187A0 (en) Novel forms of pravastatin sodium
GB0029847D0 (en) Preparation of spheroids
HUP0300557A3 (en) N-deacetylthiocolchicine derivatives and pharmaceutical compositions containing them
AU9482601A (en) Tocol-based compositions containing amiodarone
IL159614A0 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
HUP0302531A3 (en) Pharmaceutical compositions containing citalopram
HK1055685A (en) Pravastatin sodium substantially free of pravastatin lactone and epi-pravastatin, and compositions containing same
AU2001272490A1 (en) Use of galiella lactone
AU2001264324A1 (en) Method of stabilizing medicinal compositions containing pravastatin
AU2001294374A1 (en) 2-acylindenes and these containing perfume compositions
AU7057701A (en) New use as antihelmintics of albofungin and analogs
GB0000916D0 (en) New compositions of matter
ZA200204500B (en) Forms of pravastatin sodium.
AU2002216388A1 (en) Benzofuran derivatives and pharmaceutical compositions containing the same
PL340617A1 (en) Derivatives of 2-acylpyridine
TW468475U (en) Structure of gravity-suction-type perfume